Strs Ohio Lowers Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

Strs Ohio reduced its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 3.3% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 762,907 shares of the company’s stock after selling 26,238 shares during the quarter. Strs Ohio owned about 0.07% of Teva Pharmaceutical Industries worth $15,411,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. Advisors Asset Management Inc. purchased a new stake in shares of Teva Pharmaceutical Industries in the second quarter valued at about $41,000. Cromwell Holdings LLC boosted its holdings in Teva Pharmaceutical Industries by 40.3% in the 3rd quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock valued at $44,000 after purchasing an additional 629 shares in the last quarter. Sound Income Strategies LLC boosted its holdings in Teva Pharmaceutical Industries by 3,715.8% in the 2nd quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock valued at $49,000 after purchasing an additional 2,824 shares in the last quarter. MAI Capital Management increased its position in Teva Pharmaceutical Industries by 26.8% during the 2nd quarter. MAI Capital Management now owns 3,293 shares of the company’s stock worth $55,000 after purchasing an additional 697 shares during the period. Finally, JTC Employer Solutions Trustee Ltd purchased a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter worth approximately $65,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock opened at $31.83 on Monday. The firm has a market capitalization of $36.51 billion, a PE ratio of 53.05, a P/E/G ratio of 1.82 and a beta of 0.66. Teva Pharmaceutical Industries Ltd. has a 52 week low of $12.47 and a 52 week high of $33.42. The firm’s 50-day simple moving average is $29.64 and its 200 day simple moving average is $22.67. The company has a quick ratio of 0.82, a current ratio of 1.11 and a debt-to-equity ratio of 2.31.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 77,400 shares of the stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $30.24, for a total value of $2,340,576.00. Following the sale, the director directly owned 367,600 shares in the company, valued at $11,116,224. This represents a 17.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Amir Weiss sold 12,300 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $30.20, for a total transaction of $371,460.00. Following the transaction, the chief accounting officer directly owned 5,650 shares of the company’s stock, valued at approximately $170,630. This trade represents a 68.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 622,060 shares of company stock worth $17,076,965 over the last ninety days. 0.55% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on TEVA. Bank of America lifted their price target on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Barclays began coverage on shares of Teva Pharmaceutical Industries in a research report on Tuesday, December 9th. They set an “overweight” rating and a $35.00 target price on the stock. JPMorgan Chase & Co. increased their price target on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a report on Tuesday, December 16th. Jefferies Financial Group raised their price objective on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Finally, Scotiabank assumed coverage on shares of Teva Pharmaceutical Industries in a research report on Friday, December 5th. They set a “sector outperform” rating and a $35.00 target price on the stock. Three research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $33.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.